earnings The last Bristol Myers' blog post was wrong on the core thesis
Ivonescimab plus chemotherapy extended median overall survival by 4.2 months versus Tevimbra plus chemotherapy in HARMONI-6, challenging…
SMMT $10B John Hempton's Newsletter
XNAS
Summit Therapeutics Inc.
SMMT
1 article
$10B Market cap · 2026-07-30
earnings 